Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Autor principal: | |
---|---|
Outros Autores: | |
Formato: | Thesis |
Idioma: | English |
Publicado em: |
Brac University
2024
|
Assuntos: | |
Acesso em linha: | http://hdl.handle.net/10361/23931 |